Molecular Pathological Analysis of Biopsy and Autopsy Specimens from Patients Who Developed Adverse Events following COVID-19 Infection and/or COVID-19 Vaccination

Molecular Pathological Analysis of Biopsy and Autopsy Specimens from Patients Who Developed Adverse Events following COVID-19 Infection and/or COVID-19 Vaccination - Molecular Pathological Analysis of Biopsy and Autopsy Specimens from Patients Who Developed Adverse Events following COVID-19 Infection and/or COVID-19 Vaccination

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000060702

Enrollment

Registered

2026-02-18

Start date

2026-02-15

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Adverse events following COVID-19 infection and/or COVID-19 vaccination

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1.Patients who have provided written informed consent form by signing a consent form to participate in this research. In case of deceased subjects, informed consent will be obtained from a legally authorized representative. 2.Patients who have developed adverse events after COVID-19 infection and/or COVID-19 vaccination, or after blood transfusion from a donor who has received a COVID-19 vaccine. 3.Patients who have specimens collected and stored during routine clinical practice or specimens preserved by autopsy; patients who are able to provide blood samples or biopsy specimens collected in addition to routine clinical practice, or surgical specimens obtained during routine clinical practice; or patients who are able to newly provide urine or sweat samples. 4.No upper or lower age limit is set.

Exclusion criteria

Exclusion criteria: None.

Design outcomes

Primary

Measure	Time frame
Not applicable because the primary outcome is immunopathological and molecular biological analyses on an individual case basis.	—

Countries

Japan

Contacts

Public ContactShinichiro Kodama

Japanese Society for Vaccine-related Complications NA

info@jsvrc.jp0797-86-1313

Outcome results